

SEQ ID NO: 1 or an analyte thereof related to said ~~disease state~~ *myocardial infarction or renal failure*; and

means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

25. The kit of claim 18, wherein said marker includes the sequence identified as SEQ ID NO: 1 or at least one analyte thereof and said biochemical material is at least one monoclonal antibody specific therefore.

29. Polyclonal antibodies produced against the marker having a sequence identified as SEQ ID NO: 1 in at least one animal host.

30. An antibody that specifically binds a biopolymer including the marker sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

33. A process for identifying therapeutic avenues related to a ~~disease state~~ *myocardial infarction or renal failure* comprising:

conducting an analysis as provided by the kit of claim 18; and

interacting with a biopolymer including the sequence ~~identified as~~ *consisting of* SEQ ID NO: 1 or at least one analyte thereof;

whereby therapeutic avenues are developed.

34. The process for identifying therapeutic avenues related to a ~~disease state~~ *myocardial infarction or renal failure* in